| Similar Articles |
|---|
 |
Pharmaceutical Executive
November 1, 2008
Jim Wahl |
The Mess in MS A five-year forecast of the multiple-sclerosis market following the disruptions of Tysabri.   |
The Motley Fool
September 22, 2010
Jordan DiPietro |
A Huge Victory for Novartis MS oral drug is approved. |
American Journal of Nursing
July 2011
Brodkey et al. |
Living Well with Multiple Sclerosis Improvements in magnetic resonance imaging and the advent of disease-modifying therapies in the past 15 years have changed the diagnosis and treatment of multiple sclerosis |
BusinessWeek
December 30, 2009
Kerry Capell |
Multiple Sclerosis: A Breakthrough Is on the Way A number of improved treatments will be available soon, and Novartis' Fingolimod could lead the way |
The Motley Fool
September 23, 2010
Brian Orelli |
A Blockbuster in Due Time Novartis' new multiple sclerosis drug, Gilenya, isn't king yet. |
Pharmaceutical Executive
May 1, 2014
Ben Comer |
2014 Brand of the Year Brand of the Year recipients for 2014 are Copaxone, a mainstay treatment for multiple sclerosis, and KORLYM for diseases driven by excess production of the metabolic hormone, cortisol. We profile the journey of both drugs. |
The Motley Fool
September 14, 2006
Brian Lawler |
Close Failure for Genzyme Will Genzyme's Campath get approval? Investors shouldn't hold their breath. |
The Motley Fool
March 3, 2011
Brian Orelli |
3 Cheers for an FDA Rejection German drugmaker Merck said that the Food and Drug Administration had turned down its multiple sclerosis drug cladribine. The pill would have competed with Novartis' Gilenya, which gained FDA approval last year. |
The Motley Fool
October 18, 2007
Brian Lawler |
Genzyme Shows Off a Drug Candidate A top compound in development could become an important MS treatment. |
The Motley Fool
April 29, 2011
Brian Orelli |
Oral Multiple Sclerosis Drugs Heat Up Watch out Novartis and Gilenya. |
American Family Physician
November 15, 2004
Peter A. Calabresi |
Diagnosis and Management of Multiple Sclerosis The diagnosis of multiple sclerosis should be made by a physician with experience in identifying the disease. Five disease-modifying treatments for multiple sclerosis have been approved by the U.S. Food and Drug Administration. |
The Motley Fool
December 7, 2004
Charly Travers |
Spin the Medicine Bottle Is a new MS drug going to be a top seller or a bottom-dweller? Here's how to find out. Before investing in any pharmaceutical company with a product in development, go through this exercise to estimate the new drug's potential. |
Managed Care
January 2005
Thomas Morrow |
A New Approach for MS Natalizumab has received FDA approval. But as with all approved treatments, questions remain about efficacy and clinical importance compared to existing therapies. |
The Motley Fool
November 26, 2010
Anders Bylund |
Teva Is Running Scared A personal take on the MS medicine market: A little bit of marketing spin keeps the doctor away, but too much makes you a jerk. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
Multiple Sclerosis: The Advent of the Orals The $8 billion dollar multiple sclerosis market is set to double the number of available treatments in the near future, with a dramatic switch from injectables to oral medications. |
The Motley Fool
May 26, 2010
Brian Orelli |
Blockbuster Drugs Aimed at Busting MS Multiple sclerosis is a large market with more entrants coming. |
Nursing
June 2011
Daniel A. Hussar |
New Drugs 2011: Part 2 In this article, you'll learn about seven recently approved drugs, including: fingolimod hydrochloride, an oral drug indicated to treat patients with relapsing forms of multiple sclerosis. |
The Motley Fool
December 9, 2010
Brian Orelli |
Here Comes Another Oral MS Drug Good for Teva, bad for the rest. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
The Next Wave: Pharm Exec's 2011 Pipeline Report 42 of the best new drugs in development or parked at the FDA |
The Motley Fool
December 5, 2007
Brian Orelli |
Early Bird Gets the MS Worm Teva's multiple sclerosis drug COPAXONE performs well in a label-expanding trial. |
Nurse Practitioner
February 2011
Jennifer M. Belavic |
Annual Drug Update: 2010 in Review In 2010, the FDA approved several new drugs and new indications for use in primary care. From new therapies for adults with rheumatoid arthritis to a combination drug for benign prostatic hyperplasia, NPs need to be aware of the latest medications now available. |
Managed Care
May 2007
Rachel M. Renshaw |
Keys to Diabetes Control? Patience, Persistence, and Perseverance Careful attention to a comprehensive treatment plan could forestall or prevent the need to add drugs and costs to a patient's regimen. |
Pharmaceutical Executive
December 1, 2011
Ben Comer |
Pharm Exec's 2012 Pipeline Report It's a neck and neck race toward safer, faster, and medically superior treatments. Which organizations have what it takes to jockey their products into the winner's circle? |
The Motley Fool
February 2, 2011
Brian Orelli |
A Deeper Dive Into Biogen's Revenue Growth On the surface, it looks like Biogen Idec is handling the entrance of Novartis' new oral multiple sclerosis drug, Gilenya, quite well. The real picture is a little bleaker. |
The Motley Fool
September 28, 2010
Brian Orelli |
Don't Get Stuck! Invest in Needle-Free Drugs Here's how to make some money off society's general disdain for needles through next-generation drugs. |
BusinessWeek
March 14, 2005
Arnst & Barrett |
Another Ailing Miracle Drug Biogen's troubles with Tysabri are a setback for immune-system treatments |
Pharmaceutical Executive
July 30, 2007
Louis A. Morris |
Safety Net The new Culture of Drug Safety means embracing the benefit of no doubt about a product's pluses and its minuses. Pharma must learn how patients and prescribers weigh risks and how to spread the word about the advantages. |
BusinessWeek
March 10, 2011
Kanoko Matsuyama |
From Soup to MS Drug: One Fungus's Journey Gilenya, Mitsubishi Tanabe's parasite-derived pill for multiple sclerosis, could be a blockbuster. |
Pharmaceutical Executive
November 1, 2005
Alana Klein |
Direct to Consumer: A Q&A with Jim Hoyes Multiple sclerosis patients can benefit from a new kind of support system. |
The Motley Fool
June 8, 2010
Brian Orelli |
Injecting Uncertainty Into the Multiple Sclerosis Market Novartis' oral MS drug could be a blockbuster -- if it can get past the FDA. |
Pharmaceutical Executive
January 1, 2009
Amit Agarwal |
Overlooked Opportunities For pharma companies facing a difficult economic climate, pairing diagnostics with therapies offers a powerful incentive: Manufacturers can improve sales by helping physicians find the most appropriate therapeutic option. |
The Motley Fool
October 27, 2010
Brian Orelli |
Biogen Idec's Fight-Back Plan Novartis' Gilenya is coming, but Biogen has a backup plan. |
The Motley Fool
October 15, 2009
Robert Steyer |
Little Discord on Acorda Drug FDA advisory panel overwhelmingly backs a drug to improve the walking ability of multiple sclerosis patients. |
Pharmaceutical Executive
December 1, 2008
Ron Feemster |
The 2008 Pipeline Report We scrub industry's pipeline to find the drugs that everyone will be talking about in 2009 and beyond. |
American Journal of Nursing
October 2005
Charlotte Thomas-Hawkins |
Self-Management of Chronic Kidney Disease Effective management of this disease requires the patient to be the principal illness manager and this skill requires the nurses guidance and support. |
The Motley Fool
September 30, 2009
Brian Orelli |
Less Is More for Novartis That makes it simple enough. |
Pharmaceutical Executive
April 1, 2011 |
Winning Beyond the Molecule It can take both a clinical and non-clinical approach to win the differentiation competition. |
The Motley Fool
August 29, 2006
Brian Lawler |
More Good News for Rituxan Genentech and Biogen Idec's drug shows positive results against multiple sclerosis. Investors, take note. |
Pharmaceutical Executive
November 1, 2012 |
Pharm Exec's 2013 Pipeline Report In this year's report, Ben Comer reveals that drug approvals are up, as new discoveries in biology peel away symptomology to expose underlying causes. |
The Motley Fool
March 15, 2007
Brian Lawler |
Dueling Fools: Elan Bear Rebuttal With so many risks and unknowns embedded in Tysabri, investors should not be convinced Elan can provide a miracle. |
The Motley Fool
April 11, 2008
Brian Orelli |
Teva Tugs at Both Ends of the MS String Teva tries to get multiple sclerosis patients to switch to its drug. |
The Motley Fool
March 15, 2007
Brian Lawler |
Dueling Fools: Elan Bear How do you bring an Elan bear out of hibernation? Combine a crushing debt load, a huge cloud of uncertainty over its lead developmental drug program, and the launch of a new product that won't bring in enough revenue to sustain the current valuation, et voila! A bear is born. |
BusinessWeek
June 13, 2005
Catherine Arnst |
Biotech, Finally The past 30 years of biological discoveries, insights into the human genome, and exotic chemical manipulation have unleashed a wave of biological drugs, many of them reengineered human proteins. |
Nursing
June 2010
Daniel A. Hussar |
New drugs 2010, part 2 In this article, you'll learn about 14 recently marketed new drugs. |
The Motley Fool
April 12, 2011
Brian Orelli |
How Significant Is 'Statistically Significant' for Biogen? Biogen could have a third multiple sclerosis blockbuster on its hands. |
The Motley Fool
November 29, 2010
Brian Orelli |
There's Still Only One Merck KGaA's oral MS drug delay is Novartis' gain. |
The Motley Fool
September 23, 2010
Brian Orelli |
Ugly Side Effects Won't Derail This Drug Side effects don't matter much when there are no other treatment options, as in Cushing's disease. |
Pharmaceutical Executive
August 1, 2008
George Koroneos |
Hard of (Ad)hering Companies have responded to declining profits with a proliferation of patient compliance programs. But where is pharma in this paradigm shift? |
The Motley Fool
March 16, 2007
Brian Lawler |
PDL's Friend Comes Through PDL and partner Biogen advance one of their lead drug candidates. Investors, take note. |
The Motley Fool
January 21, 2011
Brian Orelli |
Trouble in Tysabri Land? Patient additions for a drug from Biogen Idec and Elan are slowing down. |
